To investigate whether MAP2K1/2 mutations are also associated with a favourable clinical response to anti-PD-1/L1 therapy, we performed data analysis using a pooled cohort consisting of three public cohorts of 253 metastatic melanoma patients treated with anti-PD-1 agents (Table S1). The gene discussed is MAP2K1; the disease is metastatic melanoma.